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Abstract
AIM: To systematically evaluate the efficacy of H2-receptor
antagonists (H2RAs) and proton pump inhibitors in healing
erosive esophagitis (EE).
METHODS: A meta-analysis was performed. A literature
search was conducted in PubMed, Medline, Embase, and
Cochrane databases to include randomized controlled
head-to-head comparative trials evaluating the efficacy
of H2RAs or proton pump inhibitors in healing EE. Relative
risk (RR) and 95% confidence interval (CI) were calculated
under a random-effects model.
RESULTS: RRs of cumulative healing rates for each
comparison at 8 wk were: high dose vs standard dose H2RAs,
1.17 (95%CI, 1.02-1.33); standard dose proton pump
inhibitors vs standard dose H2RAs, 1.59 (95%CI, 1.44-1.75);
standard dose other proton pump inhibitors vs standard
dose omeprazole, 1.06 (95%CI, 0.98-1.06). Proton pump
inhibitors produced consistently greater healing rates than
H2RAs of all doses across all grades of esophagitis, including
patients refractory to H2RAs. Healing rates achieved with
standard dose omeprazole were similar to those with other
proton pump inhibitors in all grades of esophagitis.
CONCLUSION: H2RAs are less effective for treating patients
with erosive esophagitis, especially in those with severe
forms of esophagitis. Standard dose proton pump inhibitors
are significantly more effective than H2RAs in healing
esophagitis of all grades. Proton pump inhibitors given at
the recommended dose are equally effective for healing
esophagitis.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
Key words: Erosive esophagitis; H2-receptor antagonists;
Proton pump inhibitors; Meta-analysis
Wang WH, Huang JQ, Zheng GF, Xia HHX, Wong WM, Lam
SK, Wong BCY. Head-to-head comparison of H2-receptor
antagonists and proton pump inhibitors in the treatment of
erosive esophagitis: A meta-analysis. World J Gastroenterol
2005; 11(26): 4067-4077
http://www.wjgnet.com/1007-9327/11/4067.asp
INTRODUCTION
Gastro-esophageal reflux disease (GERD) is one of the
most common chronic conditions affecting 20-40% of adult
populations and has a major adverse impact on the quality
of life[1-3]. About 40-60% of patients with symptoms of
GERD may have substantial injury of esophageal mucosa
ranging from mild inflammation and erythema to various
grades of erosions. The major complications of GERD are
esophageal ulcer and bleeding, esophageal stricture, and
Barrett’s esophagus[1-4].
Reflux esophagitis is generally considered to be the result
of prolonged and repeated exposure of the distal esophageal
mucosa to acidic gastric contents[5,6]. It is increasingly clear
that the key to reducing symptoms and to healing erosive
esophagitis is to decrease the duration of exposure to the
acidic refluxate. Acid-suppressing drugs that have been used
to treat GERD include H2-receptor antagonist (H2RAs) and
proton pump inhibitors. The efficacy of medical treatment
depends on the ability to increase and maintain the intragastric
and intra-esophageal pH above 4.0 over the 24-h period[7,8].
H2RAs are limited in their ability to inhibit postprandial gastric
acid secretion and are ineffective in controlling reflux symptoms
and healing esophagitis[9,10]. In contrast to H2RA, proton
pump inhibitors block the final step of acid secretion,
resulting in a profound and long-lasting acid suppression
regardless of the stimulus[11,12]. Results from 33 randomized
clinical trials with over 3 000 patients showed that symptomatic
relief could be anticipated in 83% of proton pump inhibitors-
treated patients compared with 60% of patients receiving
H2RAs. Similarly, esophagitis was healed in 78% and 50%
of patients treated with proton pump inhibitors and H2RAs,
respectively[13]. Previously there have been several systematic
reviews and meta-analyses of clinical trials assessing the
effects of medical treatments for erosive esophagitis[14-17].
Chiba and colleagues[14], and Caro and colleagues[15] compared
the effectiveness of proton pump inhibitors and H2RAs in
the healing of esophagitis, whereas the comparative efficacy
among proton pump inhibitors was analyzed by Sharma
et al.[16], and Edwards et al.[17]. However, comparison of the
effects between treatments with proton pump inhibitors and
H2RAs in patients with esophagitis has been difficult because
of  the difference in the study design. For example, studies
included in the previous meta-analyses were not all head-
to-head comparative trials[14,15]. The overall estimates of
healing rate calculated by one-step pooling from different pairs
of comparatives, may produce bias due to the ignorance
of study differences such as sample size and differential
difference in effect sizes. In addition, healing of esophagitis
is significantly influenced by the initial grade of esophagitis,
with healing rate being lower for the severe form of
esophagitis than for the mild form of esophagitis[18-20]. However,
no meta-analysis has been published to systematically evaluate
the impact of the initial grading of esophagitis on esophagitis
healing rates in head-to-head comparative trials. Therefore,
the objectives of the current study were firstly to evaluate
any difference in healing erosive esophagitis between proton
pump inhibitors and H2RAs in head-to-head comparative
trials, and secondly to estimate the impact of baseline grade
of esophagitis on esophagitis healing rates.
MATERIALS AND METHODS
Literature search
A computerized literature search was performed in the
PubMed, Medline, Embase and Cochrane databases for
clinical trials published in English up to May 2004 with the
following MeSH terms and/or text words in various
combinations: gastroesophageal reflux, GERD, GORD,
esophagitis, and healing, as well as the name of each
respective drug (H2-receptor antagonists: cimetidine,
ranitidine, famotidine, nizatidine, roxatidine; proton pump
inhibitors: omeprazole, lansoprazole, pantoprazole, rabap-
razole, esomeprazole). The title and abstract of all potentially
relevant studies were screened for their relevance before
retrieval of full articles. Full articles were also scrutinized for
relevance if the title and abstract were ambiguous. Fully
recursive searches were performed from the reference list
of all retrieved articles to ensure a complete and comprehensive
search of the published literature. All searches were
conducted independently by at least two reviewers.
Study selection
The inclusion criteria were as follows: (1) Randomized,
controlled clinical trials in adults with an endoscopically
confirmed diagnosis of  GERD. (2) Two or more treatment
arms: high dose vs standard dose H2RA, or an H2RA vs a
proton pump inhibitor, or a proton pump inhibitor vs a
proton pump inhibitor. (3) Healing of esophagitis was
documented by endoscopy. (4) Studies with explicit information
about the number of patients treated in each group, drug
dosage and schedule, and healing rate of esophagitis.
We excluded studies that only assessed symptom relief
without endoscopic documentation of esophagitis healing.
Also excluded were studies dealing only with relapsed or
recurrent esophagitis, studies of pediatric patients, duplicate
publications or studies published only in abstract form, or
those focusing on pharmacokinetics and pharmacodynamics.
Combination treatments such as an anti-secretory agent and
a prokinetic drug were also excluded.
Data extraction
Data was extracted from each study independently and
entered into a computerized database. Differences were
resolved by discussion to reach consensus between the
reviewers. The information retrieved covered country of
study, study design, characteristics of population, grading
of esophagitis, treatment regimen, number of patients
treated, evaluated and healed, and confounding variables
such as alcohol use, cigarette smoking, and caffeine use,
where applicable. Healing data, up to 12 wk were extracted
for both intention-to-treat (ITT) and per-protocol (PP) analyses.
Data on healing based on the initial grade of esophagitis
were also extracted, if applicable. In studies where only
per-protocol healing rates were reported, we calculated the
ITT healing rates based on the initial randomized number
of patients. Articles that did not specify the type of analysis
were assumed to report per-protocol data.
Quality assessment
Study quality was assessed by a series of validity criteria,
including study design, level of blinding, method of
randomization, patient selection, baseline characteristics,
severity of esophagitis, definition of healing, compliance,
and analysis by intention to treat criteria. Discrepancies in
quality assessment were resolved by consensus among the
authors. No quality score was assigned to any study to avoid
possible introduction of subjectivity by the authors.
Statistical analysis
The data were grouped as follows: high dose vs standard
dose H2RAs; proton pump inhibitors vs H2RAs, or one proton
pump inhibitor vs another proton pump inhibitor. We defined
standard dose of each drug as: ranitidine 300 mg/d, famotidine
40 mg/d, nizatidine 300 mg/d, cimetidine 800 mg/d,
omeprazole 20 mg/d, lansoprazole 30 mg/d, pantoprazole
40 mg/d, rabeprazole 20 mg/d, esomeprazole 40 mg/d.
The newer proton pump inhibitors include lansoprazole,
pantoprazole, rabeprazole and esomeprazole.
The outcomes considered were healing rates of
esophagitis for each group at different time points (2, 4, 6, 8,
and 12 wk), based on initial grade of esophagitis, if applicable.
Healing rate was calculated by pooling raw data from
qualified studies within each group. These data were then
expressed as a healing-time curve that plotted the cumulative
percentage of patients healed vs the end point in weeks.
Relative risk (RR) and 95% confidence interval (CI),
under a random-effects model[21], were calculated using raw
data of the selected studies at specified time points (2, 4, 6,
8, and 12 wk). The potential effect of publication bias was
assessed using a funnel plot suggested by Egger et al.[22].
4068           ISSN 1007-9327     CN 14-1219/ R     World J Gastroenterol     July 14, 2005   Volume 11   Number 26
Wang WH et al. Treatment of erosive esophagitis     4069
Statistical heterogeneity between studies was assessed using
the Q value calculated from the Mentel-Haenszel method.
In the presence of statistical heterogeneity, we searched for
the sources of any possible clinically important heterogeneity,
i.e., methodological or biological heterogeneity. We did not
simply exclude outliers on the basis of statistical test of
heterogeneity. Furthermore, to test the robustness of  the
analysis, we performed sensitivity analyses to evaluate
whether exclusion of a single study substantially altered the
result of the summary estimate.
All analyses were carried out using EasyMa software
for meta-analysis written by M Cucherat, Lyon, France
(EasyMa, 2001).
RESULTS
Study characteristics
We identified a total of  485 citations with the computerized
search. Screening of the title and abstract of the citations
identified 72 potentially relevant studies for full article retrieval.
Of these, 52 studies met the inclusion criteria[19,20,23-72], and
20 studies were subsequently excluded for the following
reasons: 17 were not head-to-head comparative studies[73-89],
1 duplicate publication[90], 1 without raw data[91], and 1
with a confusing treatment allocation[92]. The manual
search of the reference list of the retrieved articles did
not yield any additional studies. Of the 52 studies, the
majority were double blind studies (51/52, 98.1%). Ten
(19.2%) compared high dose H2RA with standard dose
H2RA
[23-32], 26 (50.0%) compared a proton pump inhibitor
with an H2RA
[33-57,71], and 16 (30.8%) compared a proton pump
inhibitor with another proton pump inhibitor[19,20,58-70,72]. Only
25 (48.1%) reported raw healing data by the initial grade of
esophagitis[19,20,23,24,30,32,35,38,43-47,49,52,53,55-58,60,61,69-71].
The proportion of patients with a smoking history was
reported in 61.5% of studies, alcohol consumption was
reported in 48.1% of studies. The initial grade of esophagitis
was reported in 58% studies. However, only 48.1% studies
provided raw data on healing by the initial grade of
esophagitis.
Healing of esophagitis
High dose H2RAs vs standard dose H2RAs  Ten studies
involving 27 treatment arms compared high dose (n = 2041
patients) with standard dose H2RAs (n = 1967 patients)[23-32].
Table 1 summarizes the pooled healing rates of  esophagitis
in patients treated with high dose H2RAs vs standard dose
H2RAs. Statistical significance was achieved at 4, 8 and 12 wk,
indicating that high dose H2RAs healed significantly more
esophagitis than did standard dose H2RAs (Table 1).
No comparative study reported data on the healing of
esophagitis at 2 wk. Only one study[29] reported healing rates
at 3 wk, of 17.2% (29/169) for high dose H2RAs and 19.6%
(33/168) for standard dose H2RAs (RR 0.87, 95%CI
0.56-1.37) (Table 1).
Proton pump inhibitors vs H2RAs There were 14 studies
with 28 treatment arms comparing standard dose proton
pump inhibitors (n = 861 patients) with standard dose H2RAs
(n = 752 patients)[33-45,71]. The pooled healing rates achieved
with the standard dose proton pump inhibitors were superior
to that of  H2RAs at all given time points (Table 2). Similar
findings were observed when the comparison was made
between high dose H2RAs (n = 234 patients) and the standard
dose proton pump inhibitors (n = 237 patients)[50,51] (Table 2).
Three studies compared low dose proton pump inhibitors
(n = 279 patients) with standard dose H2RAs (n = 276
patients) for healing esophagitis[52,53,71]. The pooled healing
rates of the low dose proton pump inhibitors were higher
than that of the standard dose H2RAs at both 4 and 8 wk
(Table 2).
Omeprazole 20 mg daily vs other proton pump inhibitors
Eleven studies with 23 treatment arms reported comparative
results on the healing of esophagitis between omeprazole
20 mg daily (n = 3 137 patients) and other proton pump
inhibitors at standard doses (n = 3 397 patients)[20,59-68]. No
significant difference in the healing rate was observed
between omeprazole 20 mg daily and other proton pump
inhibitors at 2-8 wk (Table 3).
The esophagitis healing time curves are depicted in
Figures 1-3. As shown in Figure 1, high dose H2RA achieved
higher healing rates than standard dose H2RA. However,
the healing rate achieved with standard dose proton pump
inhibitors at 2 wk was even higher than that of H2RAs at
wk 8 (63.4% vs 52.0%), suggesting that proton pump
inhibitors healed esophagitis significantly faster than did
H2RAs (Figure 2). Similar healing rates were also observed
when the newer proton pump inhibitors were compared
with omeprazole 20 mg daily (Figure 3).
Refractory esophagitis
Refractory esophagitis was defined as treatment failure with
a standard dose of H2RAs given for at least 12 wk[55-57].
Three studies compared the effectiveness of proton pump
inhibitors with ranitidine for the treatment of refractory
esophagitis[55-57] (Table 4). Two of  them reported that
lansoprazole 30 mg daily achieved significantly higher healing
Table 1  Healing rate of esophagitis by ITT with standard dose vs high dose of H2RA at 3, 4, 6, 8, 12 wk
   3-wk     4-wk      6-wk    8-wk     12-wk
Number of comparisons      1       5        9      5          12
High dose     Pooled data 29/169 297/669 607/1 294 413/669 1 142/1 729
    Pooled healing rate (%)    17.2      44.4       46.9      61.7        66.0
Standard dose     Pooled data 33/168 198/573 584/1 361 309/573 920/1 520
    Pooled healing rate (%)    19.6      34.6       42.9      53.9        60.5
Summary RR   0.874     1.281      1.096     1.165       1.084
95% CI                0.557-1.371                1.036-1.583               0.930-1.293             1.020-1.329                  1.019-1.152
ITT, intention-to-treat analysis; No, number; RR, relative risk; 95%CI.
rates than ranitidine 300 mg, daily at 4 wk (RR 1.38; 95%CI
1.31-1.83) and 8 wk (RR 2.54; 95%CI 1.86-3.46)[55,56]. The
other study indicated that treatment with high dose
omeprazole (40 mg/d) in patients refractory to H2RAs
therapy significantly improved esophagitis healing when
compared to high dose ranitidine (600 mg/d) (RR 3.69,
95%CI 2.30-5.90 at 4 wk; and RR2.03, 95%CI 1.54-2.67
at 8 wk)[57].
Healing by initial grade of esophagitis
Twenty-five studies[19,20,23,24,30,32,35,38,43-47,49,52,53,55-58,60,61,69-71] with
54 treatment arms provided raw data on healing by the initial
grade of  esophagitis (Tables 5-7). Because data by intention-
to-treat analysis were not available from the majority of
trials, the healing rate by per-protocol analysis was therefore
used.
When the healing rate was adjusted according to the
initial severity of esophagitis, no significant differences in
the healing rates was observed when patients with the severe
Figure 1  Healing-time curve of esophagitis in patients treated with H2RA.
Statistical significance was achieved at 4, 8, and 12 wk, indicating that high
dose H2RAs achieved significantly better healing rates for erosive esophagitis
than standard dose H2RAs.
Figure 2  Healing-time curve of esophagitis in patients treated with standard
doses of proton pump inhibitors vs H2RAs. At wk 2, 4, 8, proton pump inhibitors
significantly healed more patients than did H2RAs.
Figure 3  Healing-time curve of esophagitis in patients treated with standard
dose of the newer proton pump inhibitors vs omeprazole. No significant difference
in the pooled healing rates between the newer proton pump inhibitors and
omeprazole was observed.
Table 2  Healing rate of esophagitis by ITT at 2, 3, 4, 8, 12 wk comparing proton pump inhibitors (PPIs) with H2RA
PPIs H2RA
2-wk 4-wk 8-wk 12-wk                    2-wk                    4-wk                     8-wk                 12-wk
sd PPIs vs sd H2RA
Number of arms 2 13 12 2 13 12
Pooled data 116/183 577/824 640/783 60/163 271/713 350/673
Pooled healing rate (%) 63.4 70.0 81.7 36.8 38.0 52.0
Summary RR 1.759 1.832 1.586
95%CI 1.398-2.213 1.622-2.070 1.438-1.749
hd PPIs vs sd H2RA
Number of arms 4 4 1 4 4               1
Pooled data 150/204 175/201 72/80 79/211 106/207                  49/81
Pooled healing rate (%) 73.5 87.1 90.0 37.4 51.2                  60.5
Summary RR 1.722 1.623 1.488
95%CI 1.464-2.027 1.417-1.859 1.230-1.800
sd PPIs vs hd H2RA
Number of arms 2 2 2 2
Pooled data 152/235 208/235 87/234 155/234
Pooled healing rate (%) 64.7 88.5 37.2 66.2
Summary RR 1.744 1.336
95%CI 1.442-2.110 1.206-1.481
ld PPIs vs sd H2RA
Number of arms 3 3 3 3
Pooled data 187/279 219/279 120/276 161/276
Pooled healing rate (%) 67.0 78.5 43.5 58.3
Summary RR 1.605 1.374
95%CI 1.156-2.229 1.081-1.744
hd: high dose; sd: standard dose; ld: low dose; ITT, intention-to-treat analysis; No., number; RR, relative risk; 95% CI, 95% CIs.
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form of  esophagitis (  grade III) were treated with either
high dose or standard dose H2RAs. However, a significant
difference was observed for patients with grade II
esophagitis at 4 wk (Table 5). No patients with grade IV
esophagitis were included in any of the studies comparing
high dose with standard dose H2RAs.
Proton pump inhibitors achieved consistently and
significantly higher healing rates than H2RAs across all grades
of esophagitis, irrespective of the dose and duration of
treatment (Table 6). With a wide range of  CI, the superiority
of proton pump inhibitors over H2RAs was even greater
when the initial grade of esophagitis was considered in
studies of  patients with refractory esophagitis (Table 6)
despite that one study reported the same effects on grade I
esophagitis at 12 wk, when omeprazole 40 mg daily was
compared with ranitidine 300 mg daily[47]. The healing rates
Table 3  Healing rate (ITT) of esophagitis at 2, 4, 8 wk comparing PPIs with omeprazole
              Other PPIs            Omeprazole
2-wk 4-wk 8-wk 2-wk 4-wk 8-wk
sd PPIs vs sd Omeprazole
Number of arms 1 12 12 1 12 12
Pooled data 264/421 2 615/3 412 3 050/3 411 257/431 2 229/3 217 2 719/3 216
Pooled healing rate (%) 62.7 76.6 89.4 59.6 69.3 84.5
Summary RR 1.052 1.044 1.061
95%CI 0.945–1.171 0.983-1.109 0.979-1.055
ld PPIs vs sd Omeprazole
Number of arms 2 2 2 2
Pooled data 590/822 724/822 551/811 707/811
Pooled healing rate (%) 71.8 88.1 67.9 87.2
Summary RR 1.026 0.981
95%CI 0.904-1.164 0.870-1.105
sd PPIs vs hd Omeprazole
Number of arms 2 1 2 1
Pooled data 310/440 284/337 302/434 282/332
Pooled healing rate (%) 70.5 84.3 69.6 84.9
Summary RR 1.031 0.985
95%CI 0.937-1.015 0.883-1.099
hd: high dose; sd: standard dose; ld: low dose; ITT, intention-to-treat analysis; No., number; RR, relative risk; 95% CI, 95% CIs.
Table 4  Healing rate of refractory esophagitis at 2, 4, 6, 8, 12 wk comparing PPIs with H2RA
          PPIs        H2RAs
     Number of         Healing rate ( ITT )       Number of        Healing rate ( ITT )
Author Drug  Dose Patient   4 wk     8 wk    12 wk Drug   Dose Patient  4 wk   8 wk   12 wk
sd PPIs vs sd H2RA
Feldman (55)  Lan 30 o.d.      61    54/61  Ran 150 b.d.      32 12/32
Sontag (56)  Lan 30 o.d.    105 75/105   84/105  Ran 150 b.d.      54 28/54 16/541
Pooled data    166 75/105 138/166      86 28/54 28/86
Pooled rate (%)    71.4      83.1   51.9   32.6
hd PPIs vs hd H2RA
Lundell (57)  Ome 40 o.d.      51  32/51    35/51    46/51  Ran 300 b.d.      47   8/47 18/47   22/47
Ome: omeprazole; Lan: lansoprazole; Ran: ranitidine; o.d.: once daily in the morning; b.d.: twice daily; h.d.: high dose; sd: standard dose. †This study did not report
cumulative healing rate at 8 wk. All patients’ endpoint was at 8 wk. The decreased healing rate at 8 wk for ranitidine group may be due to subsequent relapse of esophagitis.
Table 5  Healing by grade with standard dose vs high dose of H2RA at 4, 6, 8, 12 wk (PP rate)
       4-wk                6-wk  8-wk        12-wk
                II    III            I                    II      III            II                III    I             II                  III
Number of arms              3    3            4                4      4          3              3    4           6 6
Standard dose Pooled data           84/190          22/105        86/137        102/266         42/180       126/187         37/105        107/129     264/383        119/256
Pooled rate (%)               44.2 21.0           62.8               38.3    23.3         67.4               35.2  82.9          69.0                46.5
High dose Pooled data          177/325        60/198      112/157       120/272         60/214       226/323         92/198        122/153          400/532        190/376
Pooled rate (%)               54.4 30.3           71.3               44.1   28.0                70.0               46.5   79.7          75.2                50.5
Summary RR
95% CI              1.231             1.430          1.136             1.150 1.200              1.039              1.316  0.962        1.032               1.059
     1.020-1.486  0.941-2.202  0.966-1.337  0.939-1.408  0.854-1.686  0.919-1.174  0.977-1.774  0.860-1.076  0.961-1.108 0.913-1.229
PP, per-protocol analysis; No., number; RR, relative risk; 95%CI.
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were similar between omeprazole and the newer proton
pump inhibitors across all grades of  esophagitis (Table 7).
Testing for between-study heterogeneity and sensitivity
analyses
In the comparison of the healing rates achieved with omeprazole
and the newer proton pump inhibitors, a significant
heterogeneity was found at 4 and 8 wk (P<0.001). However,
no further heterogeneity (P = 0.43 at 4 wk, and P = 0.92 at
8 wk) was found after exclusion of the studies from Kahrilas
et al.[67], and Richter et al.[68], suggesting that the heterogeneity
was caused by these two studies. Further scrutiny of these
two studies revealed that Helicobacter pylori (H pylori) positive
patients were excluded in both studies, whereas other studies
did not use H pylori status as an exclusion criterion. No
additional confounding factors such as the study design,
level of blinding and compliance of patients were identified.
Sensitivity analysis showed no difference in the healing rates
of erosive esophagitis between omeprazole and the newer
proton pump inhibitors (RR 1.00, 95% CI 0.96-1.04 at 4 wk;
and RR 0.99, 95% CI 0.97-1.02) when the data from the
two studies were excluded. There was no evidence of
heterogeneity in any other comparisons.
Publication bias
Tests for publication bias were assessed with funnel plots
using RRs against the sample size of each study. Due to the
inadequacy of the number of studies in each comparison,
Table 6  Healing by grade at 4, 8, 12 wk comparing PPIs with H2RAs (PP rate)
4 wk        8 wk                  12 wk
I           II                 III      IV         I                  II     III             IV           I                 II
Number of arms 2         4               3         2               5     3            1
sd PPIs Pooled data               53/60   128/162            20/54      23/23             166/178 28/47            2/3
Pooled rate (%)                 88.3        79.0                37.0       100.0                   93.3   59.6           66.7
sd H2RAs Pooled data                27/54     65/172              2/41      16/25             101/182   6/34            0/2
Pooled rate (%)                 50.0         37.8                4.9        64.0                    55.5    17.6            0
Summary RR                1.760       2.037               5.588       1.502                1.648   2.766               2.525
95%CI         1.329-2.332    1.631-2.545   1.701-18.363 1.107-2.038   1.440-1.885   1.284-5.916   1.046-6.093
No. of arms 2         4               2          2                4                    2          1              1
hd PPIs Pooled data               40/46                88/123            21/30        46/46           104/120  24/30                         29/29             42/46
Pooled rate (%)                 87.0         71.5                70.0        100.0                 86.7    80.0                          100.0               91.3
sd H2RAs Pooled data                26/50     49/126              3/28       37/49             62/121    6/28                         28/32             19/35
Pooled rate (%)                 52.0        38.9               10.7         75.5                 51.2    21.4                           87.5               54.3
Summary RR                1.665       1.835               6.110       1.300               1.689   3.626                          1.111              1.676
95%CI         1.248-2.222    1.436-2.345   2.138-17.459 1.102-1.534   1.400-2.036   1.772-7.418                  0.957-1.291  1.222-2.298
Number of arms 2         1               1           2                1       1
ld PPIs Pooled data             144/175      34/42               9/28      162/175          42/44    15/28
Pooled rate (%)                  82.3        81.0               32.1          92.6                 95.5      53.6
sd H2RAs Pooled data             104/175      15/50               1/22     132/175           27/49     2/21
Pooled rate (%)                  59.4        30.0                4.5         75.4                 55.1       9.5
Summary RR                 1.384       2.698               7.071        1.227                1.732    5.625
95%CI         1.202-1.592     1.724-4.224   0.967-51.707 1.116-1.349   1.335-2.249   1.440-21.980
Refractory esophagitis
Number of arms         1     1 2        1                2
sd PPIs Pooled data      62/77                   11/22            105/116    13/15              18/29
Pooled rate (%)        80.5  50.0                 90.5      86.7                 62.1
sd H2RAs Pooled data      20/40                     1/11               26/61       2/8                0/14
Pooled rate (%)        50.0    9.1                 42.6      25.0                0
Summary RR       1.606 5.500                2.117     3.229              35.881
95%CI                   1.158-2.228           0.835-25.337         1.575-2.845   1.034-10.091   0.728-1767.6
sd: standard dose; ld: low dose.
Table 7  Healing by grade at 4, 8 wk comparing standard dose of other PPIs vs omeprazole
       4-wk          8-wk
         I                 II      III               IV         I II      III              IV
Number of arms          3              3      3             1         3 3      3            1
sd PPIs Pooled data    195/239        302/362         148/210             3/7    214/235         329/360         175/209             2/4
Pooled rate (%)         81.6               83.4    70.5            42.9        91.1                91.4     83.7            50.0
sd omeprazole Pooled data    190/238        315/393         132/195             3/5    214/233         345/390         159/188             1/2
Pooled rate (%)         79.8                 80.2     67.8            60.0         91.8                88.5      84.6            50.0
Summary RR       1.022               1.041   1.041           0.733        0.992              1.033    0.990           1.000
95%CI 0.936-1.116   0.973-1.113   0.914-1.186   0.250-2.147 0.938-1.048   0.985-1.084   0.927-1.057   0.213-4.694
sd: standard dose.
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funnel plots did not demonstrate strong patterns. Therefore,
figures are not shown.
DISCUSSION
There have been a few systematic reviews and meta-analyses
summarizing the effect of medical treatments for reflux
esophagitis[14-17]. However, most of them suffered from
methodological flaws. The current study was the first attempt
to systematically evaluate the effects of antisecretory agents
in healing esophagitis based on head-to-head comparative
trials. We believe that analysis of  comparative trials provides
more robust results than that obtained from simple pooling
of results from non-comparative trials because no stratification
was used in the latter form of  analysis. We found that high
dose H2RAs was superior to standard dose H2RAs in healing
erosive esophagitis at wk 4, 8, and 12, and proton pump
inhibitors achieved significantly higher healing rates of
esophagitis than did H2RAs, irrespective of dose and treatment
duration. However, no statistically significant difference in
healing rates was observed between standard dose omeparzole
and the newer proton pump inhibitors after 4 and 8 wk of
treatment.
The difference in the rate of healing esophagitis between
proton pump inhibitors and H2RAs can also be expressed
as a healing-time curve for the ease of  comparison[14]. Using
this method, we have shown that proton pump inhibitors
healed esophagitis at a rate approximately twice that of H2RAs
at all time points and the healing rate achieved at 2 wk with
proton pump inhibitors was greater than that obtained with
H2RAs at 8 wk. This is consistent with the findings from
previous meta-analyses using a different study design[14-17].
H2RAs are less effective for healing esophagitis because they
cannot effectively inhibit meal-stimulated acid secretion[9,10].
Moreover, tolerance may occur to H2RAs, resulting in a
significant decrease in their anti-secretory effect[93,94].
Therefore, patients with reflux esophagitis often require high
dose H2RAs to maintain an intragastric pH above the critical
threshold of 4.0 to achieve satisfactory symptom relief and
remission of esophagitis[7,8]. Proton pump inhibitors have
been proved to be effective in suppressing gastric acid
secretion throughout the 24-h period, including meal-
stimulated acid production[95,96]. So far, tolerance to proton
pump inhibitors has not been reported in the literature even
after long-term treatment.
The severity of esophagitis is a good predictor of a
successful treatment[97]. In this analysis, we have shown that
high dose H2RAs achieved a significantly better healing rate
of esophagitis than standard dose H2RAs. However, this
difference disappeared when the results were adjusted by
the initial grade of esophagitis except for the comparison at
4 wk when high dose H2RAs healed 10% more esophagitis
(Table 5). A possible explanation for the rapid loss of
superiority of anti-secretory effect of high dose H2RAs
over standard dose H2RAs after 4 wk could be due to the
subsequent development of tolerance to the continuous
use of H2RAs
[93,94].
Our study has confirmed that proton pump inhibitors
were significantly more effective than H2RAs in healing
erosive esophagitis across all grades. In patients with mild
forms of  esophagitis (grades I and II), the healing rate achieved
with proton pump inhibitors was significantly higher than
that with H2RAs (100.0% vs 64.0% for grade I, and 93.3%
vs 55.5% for grade II) at 8 wk (Table 6). This suggested
that, even in patients with the mild form of  esophagitis,
H2RAs is a less effective treatment compared to proton
pump inhibitors. The difference was even greater in patients
with grade III/IV esophagitis. The healing rate achieved
with proton pump inhibitors at 8 wk was 59.6%, but only
17.6% with H2RAs (Table 6). In patients refractory to
H2RAs, proton pump inhibitors healed 50.0% and 62.1%
of grade IV esophagitis after 4 and 8 wk of treatment,
respectively (Table 4). Thus, proton pump inhibitors are
significantly more effective than H2RAs for treating all grades
of esophagitis, including patients refractory to H2RAs.
It is known that individual proton pump inhibitors differ
with respect to the onset of action and duration of effect
because of the variability in their bioavailability. Although
omeprazole has a relative lower bioavailability than other
proton pump inhibitors[98-100], which may contribute to the
late onset of symptom relief, this has not been translated
into a disadvantage in healing rate of esophagitis of all grades
when compared with the newer proton pump inhibitors
according to the results of this analysis.
A statistically significant heterogeneity was found in
the overall analysis comparing the efficacy of healing
esophagitis among different proton pump inhibitors. Two
studies identified to have contributed to the heterogeneity,
compared esomeprazole to omeprazole and excluded
patients with H pylori infection in their analyses[67,68]. Although
a higher healing rate of  reflux esophagitis has been observed
in patients with H pylori infection compared to uninfected
patients when treated with proton pump inhibitors[101,102],
there is no evidence that esomeprazole would work better
on H pylori negative patients. Therefore, there might in fact
be real difference in efficacy between esomeprazole and
omeprazole, because esomeprazole is the enantionmer of
omeprazole and the active compound is the achiral cyclic
sulfenamide. Comparing 40 mg of esomeprazole with
20 mg of omeprazole would be more or less the same, as
comparing double dose of omeprazole[103]. More data are
needed to further confirm the presumption.
There are several limitations in this meta-analysis. Firstly,
the quality of a meta-analysis , in general is dependent on
the quality of original studies, particularly the study design
and reporting. To correct reporting bias from original studies
is difficult and requires collaboration of investigators
involved. Because of the practical difficulties, such as lapse
in time between the time of publication and the time of
this analysis, we did not contact investigators for raw data
or clarification of unclear presentation. Secondly, three different
esophagitis grading systems were used in the individual
studies, which might have confounded the results of analyses.
Huang et al., previously reported that there is a systematic
difference in healing rates between studies using Hetzel-
Dent scoring system and those using Savary-Miller system[104].
Therefore, we considered that the impact of different
esophagitis scoring systems on the analysis of esophagitis
healing rates deserves a systematic evaluation in its own
right. This warrants an immediate consensus of using a
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standard esophagitis scoring system among investigators so
that a truly meaningful comparison of the efficacy of
different drugs can be made. Thirdly, the stratified analysis
by the initial grade of esophagitis may also be biased because
per-protocol data were used in the analysis. Fourthly, we
excluded meeting abstracts and non-English publications for
technical reasons such as inadequate reporting of outcomes
in meeting abstracts and no resources for translation of
non-English articles. This might have introduced selection
bias. To estimate the magnitude of  possible impact, we
searched the literature and identified six articles published
in non-English literature, but with an English abstract[18,105-109].
Four studies compared a standard dose proton pump inhibitor
with an H2RA, one between two H2RAs and one between
two different doses of cimetidine. The conclusions of these
trials are consistent with those of this meta-analysis. Therefore,
we believe that the inclusion of non-English studies would
not change the conclusions of this analysis. Fifthly, relief
of reflux symptoms is another important aspect in the
management of patients with GERD. However, the large
variability in measuring and reporting symptom data in the
literature prohibited us from conducting a reliable meta-
analysis of the effects of antisecretory agents on relieving
reflux symptoms. This requires an urgent attention to
establishing a standard instrument for the assessment of
symptom response in patients with GERD.
In conclusion, this meta-analysis of comparative trials
clearly identifies that H2RAs are not effective treatment
for patients with esophagitis of all grades irrespective of
dose. Proton pump inhibitors are significantly more effective
than H2RAs for healing esophagitis of all grades including
those refractory to H2RAs. No significant differences in
healing esophagitis exist among standard dose of different
proton pump inhibitors. Therefore, proton pump inhibitors
should be used for patients with esophagitis of all grades.
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